Can tiny Mustang Bio compete on the CAR-T front with giants like Novartis and Gilead? Manny Litchman aims to find out
Now that Novartis and Gilead have picked up the first two approvals for CAR-T drugs, you can expect to see rivals coming along who will probe for any weaknesses in their approach, looking to compete on the next wave of personalized cell therapies headed through the clinic.
The small crew at Mustang Bio — $MBIO, up 11% today — has some big ambitions on that score, and today they’re adding some manufacturing capacity that the company believes will be central to its ability to eventually compete with these two giants.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters